Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use

References

• RushAJTrivedaMHWisniewskiSRAcute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportAm J Psychiatry2006163111905191717074942
   PubMed Web of Science ®Google Scholar
• SchwartzTLStahlSMOptimizing antidepressant management of depression: current status and future perspectivesCryanJFLeonardBEDepression: From Psychopathology to PharmacotherapyBasel, SwitzerlandKarger201027254267
   Google Scholar
• SchwartzTLRashidAAugmentation and combination pharmacotherapy trends in major depressive disorder: results of a brief survey of psychiatristsJ Clin Pharm Ther20073212831
   Google Scholar
• BlierPWardHETremblayPLabergeLHébertCBergeronRCombination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized studyAm J Psychiatry2010167328128820008946
   PubMed Web of Science ®Google Scholar
• PapakostasGIUse of atypical antipsychotics as augmentation for treatment-resistant major depressive disorderPrimary Psychiatry20081511444720354589
   PubMedGoogle Scholar
• NelsonJCPapakostasGIAtypical antipyschotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trialsAm J Pyschiatry20091669980991
   PubMed Web of Science ®Google Scholar
• StahlSEssential Psychopharmacology: The Prescriber’s GuideCambridge, UKCambridge University Press2011
   Google Scholar
• PiesRHandbook of Essential PsychopharmacologyWashington, DCAmerican Psychiatric Press Inc1998
   Google Scholar
• HudziakGWBuspironePhiladelphia, PALipincott Williams & Wilkins2005
   Google Scholar
• OthmerEOthmerSCEffect of buspirone on sexual dysfunction in patients with generalized anxiety disorderJ Clin Psychiatry19874852012032883173
   PubMed Web of Science ®Google Scholar
• DuxonMSStarrKRUptonNLatency to paroxetine-induced anxiolysis in the rat is reduced by co-administration of the 5-HT(1A) receptor antagonist WAY100635Br J Pharmacol200013071713171910928979
   PubMed Web of Science ®Google Scholar
• HoggSDalviAAcceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonistsPharmacol Biochem Behav2004771697514724043
   PubMed Web of Science ®Google Scholar
• DawsonLAWatsonJMVilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disordersCNS Neurosci Ther200915210711719499624
   PubMed Web of Science ®Google Scholar
• Vilazodone FDA Package InsertSt Louis, MOForest Pharmaceuticals, Inc2011
   Google Scholar
• SorberaLARabassediXSilvestreJCastanerJVilazodone hydrochloride: antidepressant-5-HT1A partial agonist-5-HT reuptake inhibitorDrugs Fut2001263247252
   Web of Science ®Google Scholar
• BarowskyJSchwartzTLAn evidence based approach to augmentation and combination strategies for treatment resistant depressionPsychiatry (Edgmont)200637426120975817
   PubMedGoogle Scholar
• TrevediMHFavaMWisniewskiSRSTAR*D Study TeamMedication augmentation after the failure of SSRIs for depressionN Engl J Med2006354121243125216554526
   PubMed Web of Science ®Google Scholar
• AthanasiouMReedCRickelsKVilazodone, a novel, dual-acting antidepressant: current status, future promise and potential for individualized treatment of depressionPer Med200962217224
   Web of Science ®Google Scholar
• StahlSMEnhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatmentCNS Spectr2010152799420414154
   PubMed Web of Science ®Google Scholar
• StahlSCombining antidepressant therapies from the initiation of treatment: a paradigm shift for major depressionJ Clin Psychiatry200970111493149420031093
   PubMed Web of Science ®Google Scholar
• MaesMMeltzerHThe serotonin hypothesis of major depressionBloomFEKupferDJPyschopharmacology: The Fourth Generation of ProgressNew York, NYRaven Press2000933944
   Google Scholar
• CoplanJDWolkSKleinDAnxiety and the serotonin 1a receptorBloomFEKupferDJPyschopharmacology: The Fourth Generation of ProgressNew York, NYRaven Press2000
   Google Scholar
• PellowSChopinPFileEBrileyMValidation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the ratJ Neurosci Methods19851431491672864480
   PubMed Web of Science ®Google Scholar
• TreitDA comparison of anxiolytic and nonanxiolytic agents in the shock-probe burying test for anxiolyticsPharmacol Biochem Behav19903612032051971951
   PubMed Web of Science ®Google Scholar
• TreitDMenardJRoyanCAnxiogenic stimuli in the elevated plus- mazePharmacol Biochem Behav19934424634698446680
   PubMed Web of Science ®Google Scholar
• AdamecRBurtonPEffects of systemic injections of vilazodone, a selective serotonin reuptake inhibitor and serotonin 1A receptor agonist, on anxiety induced by predator stress in ratsEur J Pharmacol20045041–2657715507223
   PubMed Web of Science ®Google Scholar
• LuckiIThe forced swimming test as a model for core and component behavioral effects of antidepressant drugsBehav Pharmacol199786–75235329832966
   PubMed Web of Science ®Google Scholar
• PageMEDetkeMJDalviASerotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming testPyschopharmacology (Berl)19991472162167
   PubMed Web of Science ®Google Scholar
• KehneJHBartoszykGDGreinerHEIn vitro characterization of vilazodone as a dual-acting serotonin reuptake receptor and 5-HT1A receptor partial agonistPoster presented at: 65th Annual Meeting of the Society of Biological Psychiatry MeetingMay 2010New Orleans, LA
   Google Scholar
• MurckHAntonijevicLASteigerADistinct temporal pattern of the effects of combined serotonin-re-uptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy menPsychopharmacology2001155218719211401008
   PubMed Web of Science ®Google Scholar
• FramptonJEVilazodone: in major depressive disorderCNS Drugs201125761562721699273
   PubMed Web of Science ®Google Scholar
• RickelsKAthanasiouMRobinsonDSGibertiniMWhalenHReedCREvidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, doubleblind, placebo-controlled trialJ Clinical Psychiatry200970332633319284933
   PubMed Web of Science ®Google Scholar
• APA American Psychiatric AssociationDiagnostic and Statistical Manual of Mental DisordersWashington, DCAmerican Psychiatric Publishing2000
   Google Scholar
• RobinsonDSKajdaszDKGallipoliSA 1 year open-label study assessing the safety and tolerabilty of vilazodone in patients with major depressive disorderJ Clin Pyschopharamcol2011315643646
   PubMed Web of Science ®Google Scholar
• LaughrenTPGobburuJTempleRJVilazodone: clinical basis for the US Food and Drug Administration’s approval of a new antidepressantJ Clin Pyschiatry201172911661173
   PubMed Web of Science ®Google Scholar
• StahlSStahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical ApplicationsCambridge, UKCambridge University Press2008
   Google Scholar
• GrantBFHarfordTCComorbidity between DSM-IV alcohol use disorders and major depression: results of a national surveyDrug Alcohol Depend19953931972068556968
   PubMed Web of Science ®Google Scholar
• MarkovitzPJStagnoSJCalabreseJRBuspirone augmentation of fluoxetine in obsessive-compulsive disorderAm J Psychiatry199014767988002188516
   PubMed Web of Science ®Google Scholar
• McDougleCJGoodmanWKLeckmanJFLimited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorderAm J Psychiatry199315046476498465885
   PubMed Web of Science ®Google Scholar
• SchneierFRJihadBRaphaelCBuspirone in social phobiaJ Clin Psychopharmacol19931342512568376612
   PubMed Web of Science ®Google Scholar
• RabinerEAGunnRNWilkinsMRDrug action at the 5-HT(1A) receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11)C]WAY-100635Nucl Med Biol200027550951310962259
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationAmerican Psychiatric Association Practice guideline for major depressive disorder in adults. American Psychiatric AssociationAm J Psychiatry2010150126
   Google Scholar